Epigenetic Cancer Therapy (Translational Epigenetics) - Hardcover

Book 1 of 39: Translational Epigenetics
 
9780128002063: Epigenetic Cancer Therapy (Translational Epigenetics)

Synopsis

Epigenetic Cancer Therapy unites issues central to a translational audience actively seeking to understand the topic. It is ideal for cancer specialists, including oncologists and clinicians, but also provides valuable information for researchers, academics, students, governments, and decision-makers in the healthcare sector.

The text covers the basic background of the epigenome, aberrant epigenetics, and its potential as a target for cancer therapy, and includes individual chapters on the state of epigenome knowledge in specific cancers (including lung, breast, prostate, liver).

The book encompasses both large-scale intergovernmental initiatives as well as recent findings across cancer stem cells, rational drug design, clinical trials, and chemopreventative strategies. As a whole, the work articulates and raises the profile of epigenetics as a therapeutic option in the future management of cancer.

  • Concisely summarizes the therapeutic implications of recent, large-scale epigenome studies, including the cancer epigenome atlas
  • Discusses targeted isoform specific versus pan-specific inhibitors, a rational drug design approach to epigenetics relevant to pharmacoepigenetic clinical applications
  • Covers new findings in the interplay between cancer stem cells (CSCs) and drug resistance, demonstrating that epigenetic machinery is a candidate target for the eradication of these CSCs

"synopsis" may belong to another edition of this title.

About the Author

Steven Gray is a Senior Clinical Scientist and Adjunct Assistant Professor in the Thoracic Oncology Research Group, Trinity Centre for Health Sciences at St. James's Hospital, Dublin, Ireland.

From the Back Cover

Epigenetic Cancer Therapy articulates and raises the profile of epigenetics as a therapeutic option in the future management of cancer. The book covers the basic background of the epigenome, aberrant epigenetics and its potential as a target for cancer therapy, and includes individual chapters on the state of epigenome knowledge in lung, breast, prostate, liver, and other specific cancers. It also encompasses both large scale intergovernmental initiatives as well as recent findings across cancer stem cells, rational drug design, clinical trials, and chemopreventive strategies.

Epigenetics represents a unique potential therapeutic vista that is emerging at a critical time, and as it has been suggested that a 1% reduction in cancer deaths would be worth $500 billion to the USA, almost 2.5 times what it spends annually on this disease. Uniting issues central to a translational audience, Epigenetic Cancer Therapy is indispensable reading for cancer specialists and oncologists, clinicians, researchers, academics, students, government bodies, and decision makers in the healthcare sector.

"About this title" may belong to another edition of this title.